A Study of the ReCor Medical Paradise System in Clinical Hypertension

TRIO and SOLO Inclusion Criteria: * Appropriately signed and dated informed consent * Age ≥18 and ≤75 years at time of consent * Documented history of essential hypertension * SOLO Cohort only: Either an average seated office BP \< 180/110 mmHg at screening visit while on a stable regimen of 1 or 2 antihypertensive medications for at least 4 weeks prior to consent or an average seated office BP ≥ 140/90 mmHg \<180/110 mmHg despite lifestyle measures on no antihypertensive medications * TRIO Cohort only: Average seated office BP ≥ 140/90 mmHg at screening visit while on a stable regimen of at least 3 antihypertensive medications of different classes including a diuretic for at least 4 weeks prior to consent * Documented daytime ABP ≥ 135/85 mmHg and \< 170/105 mmHg after 4-week washout/run-in period (SOLO cohort) or after 4-week stabilization period (TRIO cohort) * Suitable renal anatomy compatible with the renal denervation procedure and documented by renal CTA or MRA of good quality performed within one year prior to consent (a CTA or MRA will be obtained in patients without a recent (≤1 year) renal imaging) * Able and willing to comply with all study procedures Solo Exclusion Criteria: * Renal artery anatomy on either side, ineligible for treatment including: * Main renal artery diameter \< 4 mm and \> 8 mm * Main renal artery length \< 25 mm * A single functioning kidney * Presence of abnormal kidney (or secreting adrenal) tumors * Renal artery with aneurysm …